are based on computing a maximum likelihood statistic (MLS) and are restricted to two-locus models. More recently, Cordell et al. [4] have presented a generalization of the MLS method in Cordell et al. [2] to several disease loci and affected relative pairs. Given linkage evidence at m -1 loci, the evidence at the m -th locus is measured by the difference in MLS between the best fi tting m -1 locus model and the best fi tting m locus model. However, due to the sparseness of the data when m increases and the large number of parameters that need to be estimated in their model-fi tting procedure, the method is useful in practice only for the simultaneous analysis of at most ϳ 3 disease loci. Also these methods are applicable only after a primary genome screen has already been performed, when the number of loci under investigation is small.
Here we report a new screening method. Our method works on datasets with a large number of markers and makes no assumption on the disease model, including the number of disease loci and their positions in the genome. This new approach uses the interactions among several disease loci to help increase the importance of moderate effect disease loci relative to other noisy loci. The method is based on the repetition of a two-phase selection-reduction process. In the fi rst step ('selection') we select a small set of markers at random from the available list of polymorphisms. In the next step ('reduction'), we remove the unimportant markers from the current set one by one in a stepwise fashion until all the remaining markers are important or a single marker remains (we call these markers 'returned'). At the end of this process we count how many times each marker was returned. Based on these counts we decide which markers are returned at significantly high frequency. The key technical aspect of this procedure is the defi nition of a statistic to measure the relative importance of a marker in the current set.
We apply this new approach to real data (infl ammatory bowel disease, InfBD) as well as data simulated under several complex models. The results are very good. On the real data we confi rm most of the known loci. On simulated data we show that our method is consistently more powerful than the single-locus methods currently in use.
The rest of the paper is organized as follows. In section 2 (Methods) we illustrate the theoretical aspects of our approach. In section 3 (Results) we present our fi ndings on a real dataset for InfBD and on simulated data. We conclude in Section 4 (Discussion) with a discussion of our fi ndings.
Methods

Linkage Measure
The core of our approach is the defi nition of a linkage measure for a set of markers. In this section we describe this measure.
Notation 2.1
Most model-free methods for ASPs work with the genotypic identical-by-descent (IBD) sharing at a locus, which can be 0, 1 or 2. In our approach we work with the allelic IBD status; in this case the IBD sharing can be 0 or 1, meaning the number of alleles a sibpair shares IBD transmitted from one of the parents. If the marker is not linked to disease, then the IBD sharing is 0 or 1 allele with equal probability 0.5. For several loci we defi ne an IBD sharing vector, such that the i -th component represents the sharing at the i -th locus. For example, the IBD sharing vector 111 for three loci signifi es that the sibpair shares 1 allele IBD at each of the three loci. 
where
The weight w k is chosen such that when none of the markers in the set S is linked to disease, we have:
The rationale for this is that when S contains only unlinked markers, the linkage measure should remain constant when any marker is removed from the set (no drop or increase in the linkage measure). We assume further that the k markers in S are not linked among themselves. Under these assumptions: 
Considering this it is easy to see that:
hence the resulting weight w k . It is revealing to rewrite the linkage measure as follows:
( )
Then for k 6 4 we have w k ; 1 and w k ; w k -1 . Hence we can write:
Essentially, our measure is defi ned recursively as follows. We start with the natural NPL-like measure for one marker H 1 = 2( n 1 -n 0 ) 2 . The measure for k markers ( H 1... k ) is obtained as the average of the measures for all possible k combinations of k -1 markers:
2 that measures the interaction of all k markers together.
Notice that when none of the k markers is linked to disease we have:
Thus the interaction term tends to be small in this case ( O ( N )). However when all k markers are linked to disease, this term will become large (due to E 2 [n 1 1 . .
Remark 2.2
Our experiments show that under the assumption of no specifi c interaction model (e.g. epistasis or heterogeneity), the other possible pieces of information that we could use in the defi nition of the measure (e.g. n 10 , n 01 , etc.) may introduce noise (e.g. in the case of disease loci that interact epistatically). Certainly n 10 and n 01 contain information in a two-locus heterogeneity model, but the choice of a consistent statistic that would work for different scenarios forces us to disregard these terms and instead focus on n 11 and n 00 . Notice that under both the epistatic and the heterogeneity interaction models for two disease loci E ( n 11 -n 00 ) 1 0, whereas when none of the loci is linked to disease E ( n 11 -n 00 ) = 0.
Screening Algorithm
The screening procedure consists of a marker selection-reduction process described below. Suppose we have a list of many markers (hundreds in a whole-genome study). We proceed as follows:
• Step 0: Repeat steps 1-4 B times ( B 6 3,000 is a fairly large number). • Step 1: Start by choosing a set of k ; 10 markers at random from the available list of markers. • Step 2: At each step compute for each marker in the current set the resulting change in the linkage measure when that marker is removed. For marker i :
the linkage measure decreases when removing marker i and therefore marker i is important relative to the other markers present in the current marker set. If ⌬ i 1 0, then the linkage measure increases when removing marker i and therefore marker i is not important relative to the other markers present.
• Step 3: Remove the marker i (if any) with the largest positive ⌬ i from the current set. • Step 4: Do Steps 2-3 until either all the markers in the current set are important (all ⌬ i are negative) or only one marker remains. The returned markers are recorded.
• Step 5: We compute for each marker a fi nal return count denoting the total number of times it was returned in Step 4. Based on these counts we separate the markers into two classes: the important/linked to disease markers and the unimportant/unlinked ones. The details of this statistical procedure are given in Section 2.4.
Why It Works
The behavior of the screening algorithm in section 2.2 depends heavily on the properties of the statistic H 1... k . We formulate these properties in the lemma below. The main idea is that in expectation only markers that are linked to disease are returned in Step 4 and markers that are not linked tend to be removed in Step 3. Let S = {1, ..., k } be the current set. For the lemma below we make the simplifying assumption that the k markers are not linked among themselves.
Lemma 2.3
The following properties are true: 1. If none of the markers is linked to disease, then for any marker i in S we have:
2. If S contains one marker linked to disease (without loss of generality, assume this is the fi rst marker) and the rest are unlinked, then for any unlinked marker u in S we have:
. If the set S has some interacting markers, linked to disease, of similar relative importance and some unlinked markers, then for any linked marker l and any unlinked one u we have:
4. If the current set S contains only markers linked to disease that are of similar relative importance and also have non-negligible interaction, then for any marker l in S
Proof: see Appendix A.
Remark 2.4
We made the assumption that the k selected markers in Step 1 of the Screening Algorithm are unlinked among themselves. Given that in the majority of cases the k ( ; 10) markers chosen at random from a large number of markers are unlinked among themselves and also because of ease of computation, that assumption is reasonable. However, even when some of the markers in the current set are linked, the effect tends to be very small (computations not shown), and the screening algorithm behaves as desired.
To better illustrate these properties, we simulated a small dataset with 7 markers. The fi rst two of these are each closely linked ( = 0.01) to a different disease gene. The other fi ve are unlinked to disease. The disease model is epistatic RR, i.e. two mutations at each of the two disease loci are necessary to have disease. As shown in fi gure 1 a, the measure H 12347 decreases signifi cantly when removing either one of the linked markers (1 or 2) and increases significantly when removing either of the unlinked markers (3, 4 or 7). In fi gure 1 b we see that when none of the markers in the current set is linked to disease, the values of the measure are small and not as well separated as the ones in fi gure 1 a. In fact a random (unlinked) marker is removed. In this example ( fi g. 1 b), marker 3 is removed (i.e. ⌬ 3 = H 4567 -H 34567 is the largest positive ⌬ i ). for (a) 5
Therefore according to Eq (4) the interaction term (( n 11111 -n 00000 ) 2 ) is small in this case due to the presence of unlinked markers in the current set.
Important vs. Unimportant Markers
The goal of our method is to separate the important/linked to disease markers from the unimportant/unlinked markers. We present two different methods to achieve this goal. Both methods yield a good balance between false positive results and true positive results. In our experience the two methods behave similarly.
Normal-Mixture Method
We fi rst fi t a two-component normal-mixture model to the histogram of return counts:
where 2 1 1 and p 2 = 1 -p 1 ; 2 and 1 are the means for the distribution of important and unimportant markers respectively. To control the false-positive rate (FPR), we select as threshold the 1 -␣ percentile for the unimportant markers at a certain level ␣ . The markers that have a return higher than this cutoff are claimed to be important (linked to disease genes).
Efron's Method
Another method to achieve this separation is based on an idea of Efron [5] . He proposes a method to divide the data values into two classes, interesting and uninteresting, when a large number of tests need to be evaluated as is the case in whole-genome scans. This is in contrast to the classical signifi cant versus non-signifi cant categorization used when the number of tests is small.
The method fi rst fi ts a natural spline to the histogram of return counts by Poisson regression. We call this curve: f (mixture density). Also an empirical null distribution is estimated, denoted by f 0 (empirical null density). Then for each marker M the local false discovery rate (LocFdr) is defi ned as:
Controlling the false discovery rate suggests that the markers with locfdr ! ␣ be declared interesting (for a certain level ␣ ).
Choice of B and k
As explained in section 2.2, our screening algorithm repeats B times the process of random selection of k markers and then evaluation of each of the markers in that set. We want to choose B and k large enough such that we get as clear a separation between the markers linked to disease and the unlinked ones as possible. We present a heuristic derivation of a formula for B in the Appendix. The formula predicts conservatively that for 200 markers B should be about 8,000 and for 500 markers B ; 20,000. The size of k infl uences the number of times certain markers are chosen together in the random subset. It should not be too small, since we want a good probability to select markers together. On the other hand, due to the sparseness of the data in large dimensions and also due to computational issues, k should not be too large. In our experience k = 10 works well.
Results
We evaluated our method on both simulated data and real data.
Application to Simulated Data
We applied our method to two complex disease models.
First Simulated Disease Model
In the fi rst disease model there are 9 unlinked disease loci. The disease is present when at least 5 of the 9 disease genes are mutated. The sample contains 200 ASPs genotyped at 50 markers, with 20% of the data sporadic (diseased because of nongenetic causes). Nine markers out of the total of 50 are linked to disease genes ( = 0.05), one marker for each disease gene. The rest are independent markers, not linked to disease and among themselves. The disease gene frequencies are all set to 0.05 and the marker frequencies are all 0.5. We assume we have complete data: the inference of the IBD sharing is without ambiguity. For each marker we compute two statistics:
• the single-locus statistic (the ASP mean test):
where n 1 ( n 0 ) is the number of 1 (0) IBD sharing at that particular marker.
• the return count computed by the proposed method ( B = 3000 and k = 10 in our screening procedure). For each of the two methods we report the number of loci above certain signifi cance thresholds: {1, 2, ..., 10%} false positive rates. Since in the simulated data we know exactly which markers are linked to disease and which are unlinked, we can approximate the threshold corresponding to a specifi c false positive rate empirically by simulation. Figure 2 shows an example of a simulated dataset according to the complex model outlined above. The horizontal lines represent the thresholds for the 1, 2, 5 and 10% FPR. It illustrates the advantage of our method; because the markers linked to disease are returned together in Step 4 of the screening algorithm in section 2.2, they will separate better from the unlinked markers. Therefore the proposed method can be very powerful in increasing the importance of disease loci of moderate effect by making use of interactions among disease loci.
To investigate the power, we generated 600 independent replicates. Figure 3 a depicts the average percentage of disease loci selected by each of the two methods while keeping the false positive rate at the {1, 2, ..., 10%} level. Our method is more powerful than the single-locus method at all levels. At the 1% signifi cance level, our method discovers on average 3.1 of the 9 disease loci, while the single-locus method fi nds only 2.2 loci. Similarly at the 3% level we detect on average 4.5 loci, while the singlelocus method fi nds 3.4 loci.
Finally, we compared the increase in sample size necessary for the single-locus method to achieve similar power to that of the multilocus method. The results are depicted in fi gure 3 b. For this particular model an increase in sample size of over 20% is necessary.
Second Simulated Disease Model
We also simulated a similar disease model with 4 disease loci. Now the disease is present when at least 2 of the 4 disease genes are mutated. Figure 4 a depicts the average percentage of disease loci selected by each of the two methods while keeping the false positive rate at the {1, 2, ..., 10%} level. As we can see, our method is more powerful than the single-locus method at all signifi cance levels. In fi gure 4 b we illustrate the increase in sample size necessary for the single-locus method to attain similar power to that of the multilocus method. For this simpler disease model, a 10-15% increase is necessary.
We then repeated the same simulations, but this time we introduced small linkage disequilibrium (LD) levels between some of the disease genes and the nearby linked markers. Namely, ␦ 1 = ␦ 2 = 0.5 and ␦ 3 = ␦ 4 = 0 where ␦ is the normalized LD measure. We compared the single-locus approach to a modifi ed version of our multilocus linkage method (see Appendix D) that can also take advantage of mild linkage disequilibrium between disease loci and nearby markers. In this case the results ( fi g. 5 ) are even better compared to the ones obtained in fi gure 4 where no linkage disequilibrium was present. The improvement at the 1% FPR is 23% and an increase in sample size of over 25% is necessary for the single-locus linkage method to achieve similar performance as the modifi ed multilocus linkage method.
Application to Real Data (Infl ammatory Bowel Disease)
We also analyzed a real dataset for InfBD using our method. InfBD consists of two disorders: Crohn's Disease (CD) and Ulcerative colitis (UC). They are both infl ammatory disorders of the gastrointestinal tract with a strong genetic contribution as revealed by epidemiological stud- The present dataset is a genome screen of 106 ASPs (including parents) from Canada, affected with CD genotyped at 457 microsatellite markers; the average marker spacing is ϳ 10 cM. These data have been previously analyzed in Rioux et al. [7] and in Lo and Zheng [8] . In order to apply our new approach to these data, we fi rst inferred the IBD sharing probabilities for each ASP using the program GENEHUNTER 2.0 (Daly et al. [9] ). Since our method requires complete IBD sharing information, we probabilistically impute the IBD sharing values. More exactly, for each sib pair under study we generate the IBD value at each position in the sharing vector according to the corresponding sharing probabilities (as calculated by GENEHUNTER 2.0); for example if the sharing probabilities at a certain position are (0.2, 0.5, 0.3) for sharing 0, 1 and 2 alleles respectively, then we generate the IBD value 0, 1 or 2 according to this distribution. In order to minimize the bias due to these probabilistic imputations, we do it 100 times, each time generating a new dataset.
We applied our algorithm on each of the 100 generated datasets. We use B = 20,000 and k = 10 in our screening procedure. The return counts (averaged over the 100 datasets) for all markers together with the fi tted two-component normal mixture are depicted in fi gure 6 b. By controlling the false positive rate at a stringent level we obtain that markers with return count above 240 should be reported as important. In fi gure 6 a we depict the cumulative distribution function (CDF) for a single normal fi tted to the data versus the CDF for a mixture of two normals.
We also applied Efron's approach and by using a 1% cutoff for the LocFdr, we obtain similar results (see Appendix C).
In fi gure 7 we show the return counts plotted versus marker locations in the genome. The mean return count is 140 and is marked by a horizontal solid line. The threshold for declaring a marker important is 240 and is marked by a broken line.
The results we obtain are extremely signifi cant. We validated 6 (IBD1, IBD3, IBD5, IBD6, IBD7, IBD8) of the 8 known InfBD loci. Additionally, we found several other interesting regions. 1 The region 1q21 contains a cluster of genes infl uencing epidermal differentiation. This region is linked to other infl ammatory diseases, e.g. psoriasis; psoriasis can occur in association with InfBD (Crohn's disease), suggesting that they may share common genetic risk factors. 2 The locus on chromosome 2p11 (D2S1790) is located ϳ 10 cM from the gene IL1R1 (interleukin 1 receptor, type 1). There is evidence for the activation of the mucosal immune system and the production of infl ammatory cytokines, i.e. interleukin (IL)-1ra and IL-1beta, in the InfBD (Heresbach et al. [10] ). The region 2q32 harbors the STAT1 and STAT4 genes (signal transducers and activators of transcription), which are candidate genes for InfBD (Barmada et al. [11] ). 4 The locus on chromosome 3p: suggestive linkage in this region was found in Rioux et al. [7] . 5 The locus on chromosome 7p13: gene IGFBP3 (insulin-like growth factor binding protein 3) maps to this region. Katsanos et al. [12] found that the serum IGFBP3 levels are reduced in patients with InfBD.
6 The locus on chromosome 21q22.2 (D21S1809) is close to the TFF1 and TFF2 (trefoil factor 1 and 2) genes. These genes, located on 21q22.3, are expressed in the gastrointestinal mucosa. Increased levels of TFF1 and TFF2 have been found in serum from InfBD patients (Vestergaard et al. [13] ).
In Appendix E we give the table with all selected markers and their chromosomal positions. 
Discussion
We presented a new model-free multilocus linkage method for affected sib pairs. Our approach selects from a large number of polymorphisms a small number that appear to be linked to disease. No assumption is made on the disease model, including number of disease loci or their positions in the genome. It uses both the marginal linkage information as well as information coming from the possible interaction among several disease loci to boost the signifi cance of modest single-locus effects. A further advantage of our method is that it can be naturally extended to take into consideration small linkage disequilibrium levels between disease loci and nearby markers, thereby gaining even greater increases in power over single-locus linkage methods. Further details on this method will appear in a paper under preparation.
We evaluated our method on both simulated data and real data. The extensive simulations that we did show consistently that the proposed approach is more powerful than the conventional single-locus linkage methods at all signifi cance levels (up to 40% increase in power). The improvement in power increases when the number of interacting disease loci increases. In the absence of interactions our method performs similarly to the single-locus methods. Also the results on the real data are highly signifi cant. We validated 6 of the 8 known InfBD loci and also found a few interesting loci, some of which have been already implicated in InfBD pathogenesis.
Our method is also very general; the disease loci can be anywhere in the genome (possibly on different chromosomes) and they can interact in complex, unknown ways. We did make a simplifying assumption, namely we assumed that the selected markers in the current set are unlinked among themselves. It is clear, however, that the effect of linkage between two unimportant markers is superseded by the presence in the current set of a marker linked to disease. This point is best illustrated on real data, where we see that markers close together do not tend to have return counts higher than expected (e.g. chromosome 4 in fi gure 7 ).
The software implementing the proposed methods is available from the authors upon request. A complete package will be available online soon.
Given the complex nature of the common diseases and the many challenges in genome-wide scans, we believe that our approach is very relevant; by using both the marginal and the interaction information, our method performs better than the traditional single-locus methods.
Also due to its generality, the proposed method is applicable to a large number of situations.
It suffi ces to show that ( ) ( )
(we also use w k ! w k -1 ). We prove the fi rst inequality, namely
Since markers 2, ..., k are not linked to disease and among themselves, one can easily show that E[ H 2... k ] = 2 N where N is twice the number of ASPs. Therefore we need to show that ( ) (
Now we have:
1 is the probability of the IBD sharing vector 1...1 at loci 1... k . Therefore we showed the fi rst inequality.
For the second inequality in (*),
we proceed as follows. By defi nition in section 2. 1 we have: 
It suffi ces to show that
Using (5) it is easy to prove that E[( n 
where N is twice the number of ASPs. Hence what we need to prove is that:
If we let p 1 = rp 0 with r 1 1 and since p 1 + p 0 = 1 we obtain: ( 
The latter inequality is true for N (twice the number of ASPs) large enough. For example when r = p 1 / p 0 = 1.3 and k = 2, a sample of 60 ASPs is suffi cient. Hence we have shown that (7) is true. Now we can complete the proof of the second inequality in (*). If marker 1 is linked to disease and marker u is not linked, then we have: (6) and together with the inequalities above we obtain the second inequality in (*). This completes our proof.
3. We assume k 6 4 ( k = 2 and k = 3 can be proved using caseby-case computations). We assume the fi rst t markers are linked to disease and the rest ( k -t ) ( 1 0) are unlinked.
Let 
From this we have:
We show that:
and therefore E[
From (6) we can write:
With (8) and (9), we need to show:
Now:
where we used the fact that the last k -t markers are not linked to disease and among themselves (hence p
. From this and (10) follows that we need to prove that: 
This inequality is similar to inequality (**) shown at point 2. of the lemma for the case t = 1. For N large enough and when t is small compared with k it is true. ii) If t is comparable to k and since k 6 4 (from our assumption), then p This concludes our proof for t (the number of markers linked to disease) between 2 and k -1. Next we show the case t = k .
4. We prove the case k 6 4. The cases k = 2 and k = 3 can be verifi ed easily through direct case-by-case computations. We use the approximation in section 2.1 and since the interacting disease loci have similar importance we obtain:
In order to clearly separate the markers linked to disease from the ones not linked, we require:
After some algebra, this can be written equivalently as: We can estimate p 0 , the probability for a marker not linked to disease to be selected and returned in a single repetition, as follows: 0 returned selected and unlinked selected unlinked
where n is the total number of markers and k is a small number of markers (say 10) selected to be evaluated; we assume conservatively that the probability that a selected marker, not linked to disease, is returned is 1/ k . Therefore we obtain where 1 -is an estimate for the probability that a linked marker, once selected, is returned. If conservatively we take r = 2 we obtain B ; 41( n -1).
Appendix C
Efron's Approach to Separating the Important from the Unimportant Markers
We also applied Efron's method [5] for separating the set of markers into two categories: important vs unimportant. In fi gure 8 we give the results. On the left-hand side, the histogram of the return counts together with the fi tted empirical null density f 0( z ) and the mixture density f ( z ) are depicted. On the right-hand side, the LocFdr plot is added to the histogram (scaled up by a factor of 50). A return count of 242 corresponds to a LocFdr of 1%.
Appendix D
Extension of the Multilocus Linkage Method
We give a natural extension of the multilocus linkage method so that mild linkage disequilibrium (LD) levels between disease loci and marker loci can be used in addition to linkage to obtain even greater increases in power over single-locus linkage methods. The extension is based on combining the multilocus linkage method with a similar association method (the BHTA algorithm, Lo and Zheng [6] ). They are both based on the screening procedure in section 2.2. In what follows we denote by ⌬ L i (called ⌬ i in the main text) and ⌬ LD i (defi ned in Lo and Zheng [6] ) the change in linkage and association information respectively when removing marker i from the current set.
• Step 0: Repeat steps 1-4 B times.
• Step 1: Start by choosing a set of k ; 10 markers at random from the available list of markers. We compute for each marker a fi nal return count denoting the total number of times it was returned in Step 4. Based on these counts we separate the markers into two classes: the unimportant (unlinked) markers and the important (linked AND/OR associated) ones. This simple procedure guarantees that when evaluating a marker we consider both the marginal information, as well as the interaction information contained in a dataset. Also it takes into account two pieces of information, usually treated separately: linkage information and linkage disequilibrium information. We are currently preparing a separate paper with the details of this combined procedure. Table 1 lists the markers we claim important together with their chromosomal position (InfBD dataset).
Appendix E
Results on Real Data
